A new trading day began on Tuesday, with Tscan Therapeutics Inc (NASDAQ: TCRX) stock price up 4.13% from the previous day of trading, before settling in for the closing price of $5.08. TCRX’s price has ranged from $3.73 to $9.69 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 230.91% over the last five years. Meanwhile, its annual earnings per share averaged 4.37%. With a float of $41.65 million, this company’s outstanding shares have now reached $43.55 million.
The firm has a total of 154 workers. Let’s measure their productivity. In terms of profitability, gross margin is 59.54%, operating margin of -914.69%, and the pretax margin is -855.84%.
Tscan Therapeutics Inc (TCRX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Tscan Therapeutics Inc is 21.37%, while institutional ownership is 78.81%. The most recent insider transaction that took place on Sep 23 ’24, was worth 26,450. In this transaction Director of this company bought 5,000 shares at a rate of $5.29, taking the stock ownership to the 45,000 shares. Before that another transaction happened on Aug 23 ’24, when Company’s Director bought 5,000 for $5.69, making the entire transaction worth $28,450. This insider now owns 35,000 shares in total.
Tscan Therapeutics Inc (TCRX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 4.37% per share during the next fiscal year.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Here are Tscan Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.92, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
Analysing the last 5-days average volume posted by the [Tscan Therapeutics Inc, TCRX], we can find that recorded value of 0.25 million was better than the volume posted last year of 0.24 million. As of the previous 9 days, the stock’s Stochastic %D was 56.17%. Additionally, its Average True Range was 0.32.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 16.71%, which indicates a significant decrease from 52.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.50% in the past 14 days, which was lower than the 60.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.34, while its 200-day Moving Average is $6.61. Now, the first resistance to watch is $5.82. This is followed by the second major resistance level at $6.36. The third major resistance level sits at $6.73. If the price goes on to break the first support level at $4.91, it is likely to go to the next support level at $4.54. Now, if the price goes above the second support level, the third support stands at $4.00.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
With a market capitalization of 280.23 million, the company has a total of 52,974K Shares Outstanding. Currently, annual sales are 21,050 K while annual income is -89,220 K. The company’s previous quarter sales were 540 K while its latest quarter income was -31,660 K.
